Multivariable Cox regression analysis of factors associated with overall survival, disease-free survival and distant metastasis-free survival in the training and validation cohorts
| Training cohort (n=221) | Validation cohort (n=115) | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Variable | ||||
| Overall survival | ||||
| IS (3–6 vs 0–2) | 0.34 (0.18 to 0.63) | 0.001 | 0.42 (0.21 to 0.84) | 0.014 |
| TNM Stage (III–IV vs I–II) | 3.49 (1.23 to 9.87) | 0.019 | 10.7 (1.46 to 78.9) | 0.020 |
| EBV-DNA (>2000 vs ≤2000) | 1.96 (1.01 to 3.78) | 0.045 | NA | NA |
| Disease-free survival | ||||
| IS (3–6 vs 0–2) | 0.44 (0.25 to 0.78) | 0.005 | 0.37 (0.20 to 0.68) | 0.001 |
| TNM stage (III–IV vs I–II) | 2.79 (1.18 to 6.62) | 0.020 | 7.01 (1.68 to 29.2) | 0.007 |
| EBV-DNA (>2000 vs ≤2000) | 2.13 (1.18 to 3.86) | 0.013 | NA | NA |
| Distant metastasis-free survival | ||||
| IS (3–6 vs 0–2) | 0.43 (0.21 to 0.87) | 0.019 | 0.32 (0.14 to 0.75) | 0.008 |
| TNM stage (III–IV vs I–II) | 3.52 (1.06 to 11.7) | 0.040 | 7.68 (1.02 to 58.0) | 0.048 |
| EBV-DNA (>2000 vs ≤2000) | 2.31 (1.08 to 4.93) | 0.031 | NA | NA |
Bold values were considered significant
EBV, Epstein-Barr virus; IS, immune score; NA, not applicable; TNM, tumor-node-metastasis.